eFFECTOR Therapeutics, Inc. is placing its bets on a breast cancer drug candidate following the failure in a mid-stage trial of tomivosertib for non-small cell lung cancer (NSCLC), an indication where some had forecast blockbuster sales. However, the company is not yet giving up on tomivosertib, which is also in early-stage development for acute myeloid leukemia (AML).
The biotech company announced 4 April that the Phase II KICKSTART trial combining tomivosertib with Merck & Co., Inc.’s PD-1 checkpoint inhibitor Keytruda (pembrolizumab) in patients with frontline NSCLC...
Key Takeaways
-
eFFECTOR Therapeutics said tomivosertib did not show sufficient efficacy in the Phase II KICKSTART trial combining it with Merck’s Keytruda in NSCLC.
-
The...